Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03458520 · ClinicalTrials.gov registry record
Pediatric PET/MR Image Registry
A clinical trial of Lymphoma and Osteosarcoma, sponsored by Stanford University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT03458520: Recruiting study of Lymphoma and Osteosarcoma, sponsored by Stanford University.
NCT03458520 is a study of Lymphoma and Osteosarcoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 100 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03458520, a study of Lymphoma and Osteosarcoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.
Primary Outcome
Number of tumors detected on whole body MRI, PET/MR and (if available) PET/CT scans.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PET/CT imaging
- DIAGNOSTIC_TEST PET/MR imaging
- DIAGNOSTIC_TEST MR imaging
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2026-12-31 |
What NCT03458520 shows while recruiting
NCT03458520 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which PET/CT imaging is the first listed.
NCT03458520 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03458520 about?
NCT03458520 is a clinical study titled "Pediatric PET/MR Image Registry". The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic ...
What is the current status of trial NCT03458520?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2018-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03458520 study?
This clinical trial studies the following conditions: Lymphoma, Osteosarcoma, Soft Tissue.
What interventions are being tested in trial NCT03458520?
The interventions under investigation include: PET/CT imaging (DIAGNOSTIC_TEST), PET/MR imaging (DIAGNOSTIC_TEST), MR imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03458520?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03458520 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03458520's enrollment target sits among peer trials
100 81st of 299 higher than 213 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI